Tuesday, July 30, 2013 3:55:16 PM
The one company that's going the long route (originally but maybe not by the time we're done) is Synthon. They are close to finishing up a worldwide phase III study comparing their generic Copaxone to the original.
Many of their testing sites are completed already. Now if they have good results, would the FDA insist that the others follow or if they have good results and Momenta/Mylan be the same would it be a shoe-in.
IF their results are bad it could mean the same.
ECGI Building in Crypto's Top-Performing Sector as Tokenized Real-World Assets Surge Past $26 Billion • ECGI • Mar 19, 2026 8:30 AM
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • BLOZF • Mar 16, 2026 8:37 AM
